预防博莱霉素化疗导致卵巢癌患者肺毒性的药学监护  

Pharmaceutical care for protecting an ovarian cancer patient from bleomycin pulmonary toxicity

作　　者：李静姿[1] 周颖[1] 崔一民[1] 

机构地区：[1]北京大学第一医院药剂科,北京100034

出　　处：《中国临床药理学杂志》2014年第5期456-457,共2页The Chinese Journal of Clinical Pharmacology

摘　　要：目的探讨对极量后继续应用博莱霉素的患者如何预防肺损害的药学监护模式。方法通过参与1例卵巢癌患者极量后继续应用博莱霉素进行姑息化疗的治疗过程,协助临床医师针对博来霉素的潜在肺毒性制定治疗方案。结果与结论从预防、监测、治疗3个方面,为晚期癌症姑息化疗的患者,制定合理的个体化给药方案,预防和监护化疗药物所致不良反应的发生发展,最大限度地提高患者的生活质量。Objective To provide the pharmaceutical care plan for pa- tients receiving bleomycin, which has reached toxicity dose, to prevent the drug -induced pulmonary injury. Methods Regimen was laid down for aiding doctors to prevent the potential pulmonary toxicity through tak- ing part in the therapeutic process of an ovarian cancer patient given ble- omycin which has reached toxicity dose. Results and Conclusion From three aspects of preventing, monitoring and treating, a reasonable indi- vidualized dosing regimen for patients with advanced cancer palliative care was devoleped. The adverse reactions of chemotherapy should be monitored and prevented for enhancing the quality of patients＇ life.

关 键 词：博莱霉素 肺毒性 药物性肺损害 药学监护 

分 类 号：R979.1[医药卫生—药品] R737.31[医药卫生—药学]